舒更葡糖与新斯的明对术后肺部并发症关联的回顾性登记分析
本研究基于范德堡大学医学中心2010至2019年NSQIP数据库,纳入10491例全麻患者,比较舒更葡糖与新斯的明拮抗非去极化肌松药后术后肺部并发症风险。倾向评分加权后,舒更葡糖组术后肺部并发症比值无显著差异(aOR 0.89,95%CI 0.65–1.22,P=0.468),切换拮抗剂与并发症发生无关。
要点
- 单中心回顾性队列中,舒更葡糖与新斯的明术后肺部并发症风险无显著差异。
- 总体术后肺部并发症发生率5.5%(新斯的明5.9% vs 舒更葡糖4.2%)。
- 倾向评分调整后,随时间推移术后肺部并发症绝对发生率降低(aOR 0.91/年)。
核心结论
- 在10491例单中心三级学术医疗中心患者中,切换神经肌肉阻滞拮抗剂与术后肺部并发症发生无关。
研究设计与样本
- 观察性队列研究,基于范德堡大学医学中心NSQIP数据库,纳入2010年1月至2019年7月全麻下接受非去极化肌松药拮抗的成人患者。
- 共10491例 eligible 病例,其中7800例接受新斯的明,2691例接受舒更葡糖;采用逆概率治疗加权倾向评分分析控制混杂。
主要发现
- 575例(5.5%)发生术后肺部并发症:新斯的明组5.9%,舒更葡糖组4.2%。
- 肺炎306例(2.9%;新斯的明3.2% vs 舒更葡糖2.1%),延长机械通气113例(1.1%;1.1% vs 1.1%),非计划插管156例(1.5%;1.6% vs 1.0%)。
- 舒更葡糖与新斯的明相比,术后肺部并发症比值无差异(aOR 0.89;95%CI 0.65–1.22;P=0.468)。
临床怎么用
- 对于接受非去极化肌松药全麻的成人患者,选择舒更葡糖或新斯的明拮抗不应仅基于降低术后肺部并发症的预期。
- 术后肺部并发症风险随时间下降,提示围术期管理整体改善可能比单一拮抗剂选择更重要。
局限性
- 单中心回顾性观察性设计,可能存在未测量混杂。
- 研究期间发生拮抗剂整体切换,时间趋势可能影响结果。
- 术后肺部并发症通过回顾性病历审查确定,可能存在错分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative residual neuromuscular blockade related to nondepolarizing neuromuscular blocking agents may be associated with pulmonary complications. In this study, the authors sought to determine whether sugammadex was associated with a lower risk of postoperative pulmonary complications in comparison with neostigmine. METHODS: Adult patients from the Vanderbilt University Medical Center National Surgical Quality Improvement Program database who underwent general anesthesia procedures between January 2010 and July 2019 were included in an observational cohort study. In early 2017, a wholesale switch from neostigmine to sugammadex occurred at Vanderbilt University Medical Center. The authors therefore identified all patients receiving nondepolarizing neuromuscular blockades and reversal with neostigmine or sugammadex. An inverse probability of treatment weighting propensity score analysis approach was applied to control for measured confounding. The primary outcome was postoperative pulmonary complications, determined by retrospective chart review and defined as the composite of the three postoperative respiratory occurrences: pneumonia, prolonged mechanical ventilation, and unplanned intubation. RESULTS: Of 10,491 eligible cases, 7,800 patients received neostigmine, and 2,691 received sugammadex. A total of 575 (5.5%) patients experienced postoperative pulmonary complications (5.9% neostigmine vs. 4.2% sugammadex). Specifically, 306 (2.9%) patients had pneumonia (3.2% vs. 2.1%), 113 (1.1%) prolonged mechanical ventilation (1.1% vs. 1.1%), and 156 (1.5%) unplanned intubation (1.6% vs. 1.0%). After propensity score adjustment, the authors found a lower absolute incidence rate of postoperative pulmonary complications over time (adjusted odds ratio, 0.91 [per year]; 95% CI, 0.87 to 0.96; P < .001). No difference was observed on the odds of postoperative pulmonary complications in patients receiving sugammadex in comparison with neostigmine (adjusted odds ratio, 0.89; 95% CI, 0.65 to 1.22; P = 0.468). CONCLUSIONS: Among 10,491 patients at a single academic tertiary care center, the authors found that switching neuromuscular blockade reversal agents was not associated with the occurrence of postoperative pulmonary complications.
引用
- Li G, Freundlich RE, Gupta RK, et al. Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis. Anesthesiology. 2021. PMID: 33730169. doi:10.1097/ALN.0000000000003735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。